BioCentury
ARTICLE | Company News

Clinigen Group, Novartis sales and marketing update

April 1, 2013 7:00 AM UTC

Clinigen acquired Cardioxane dexrazoxane from Novartis for $33 million in cash, which will be paid in two tranches. Clinigen said it plans to "revitalize" the product through "new commercialization, ...